104¦~3¤ë¸¹ ¹D ªk ªk °T (275)

DEEP & FAR

 

 

 

 

ANDA-½×¤ÎÃľDzզXª«»P²Ä¤K±øÁn©ú~Fed. Cir.2012 (¤Q¥|)

 

 

³¯ºaºÖ ±M§Q¥N²z¤H

¡E¤¤°êÂåÃľǰ|ÃľǨt¾Ç¤h

¡E¤é¥»ºÖ©£¤j¾Ç¥ÍÃľǩҺӤh

¡E¶§©ú¤j¾ÇÂå¾ÇÃIJz©Ò³Õ¤h

 

¥»°|´¿¦bWarner-Lambert®×»{©w¡A¤@ºØÃĪ«¥Îªk¤§±M§Q¡A¶È¦b®Ú¾Ú¡± 271(e)(2) »¼¥æ²¤Æ·sÃĥӽР(Abbreviated New Drug Applications, ANDA)¥Ó½Ð¡A¥H´M¨D¦æ¾P¤w¸g®Ö­ã¥ÎªkÃĪ«¤§¤W¥«¡Aºc¦¨«IÅv¡C(filing an ANDA for a drug having any patented use automatically constitutes infringement under ¡± 271(e)(2).) ¦]¦¹¡A©Ò´M¨D¤W¥«¦æ¾P¤§ANDA¥Ó½Ð¤º®e­Y¥¼²[»\©ó¤@ÃľDzզXª«±M§Q¡A¥BÄÝ©ó«D±M§Q¤§ªvÀø¤èªk¡A«h®Ú¾Ú¡± 271(e)(2) ¨Ã¥¼ºc¦¨«IÅv(a patented method of using a drug can only be infringed under ¡± 271(e)(2) by filing an ANDA that seeks approval to market the drug for that use. Thus, an ANDA seeking to market a drug not covered by a composition patent for unpatented methods of treatment cannot infringe under ¡± 271(e)(2). [1])¡Cªü´µ§Q±¶§Q±d¨Ã¥¼±±¶D¡A¥ç¥¼ÁnºÙ¡A³Q¤W¶D¤H¤§ANDA«Y´M¨D¬ü°ê­¹«~ÃÄ«~ºÞ²z§½(FDA) ®Ö­ã·çµÎ¥ï¥L¥Å¶t¤§¥Î³~¡A¦Ó¬°²Ä¡¦618¸¹©Î²Ä¡¦152 ¸¹±M§Q©Ò²[»\¡A­Ú¾Ú¥H¬° ¡± 271(e)(2)¤§½Ð¨D(AstraZeneca has not alleged, nor could it allege, that Appellees¡¦ ANDAs seek FDA approval for uses of rosuvastatin calcium covered by the ¡¦618 or ¡¦152 pat-ents as would be required to state a viable ¡± 271(e)(2) claim.)¡C

ªü´µ§Q±¶§Q±d¸Õ¹Ï°Ï¤ÀWarner-Lambert®×»P¨ä¦b¥»®×¤§¨Æ¹ê®t²§¡A»{¬°¥»®×©Ò¥D±i«Y¥¼¸g®Ö­ã©Î¡¨«D¼ÐÅÒ¤§¥Î³~¡¨(off-label use) ¤§±M§Q¡A¦Óªü´µ§Q±¶§Q±d¤§²Ä¡¦618¸¹©M²Ä¡¦152¸¹±M§Q«Y±Ô­z FDA ©Ò®Ö­ã·çµÎ¥ï¥L¥Å¶t¤§¥Î³~¡Cªü´µ§Q±¶§Q±d¥D±i±M§Q«ù¦³¤H»Ý¸g¾ú¬Û·í§V¤O¤Î¸ê·½¡A¤è¯àÀò±o¬ü°ê­¹«~ÃÄ«~ºÞ²z§½®Ö­ã¨ä±M§Q¤èªk¤§¨Ï¥Î¡A¾Ç¦WÃÄ»s³y°Ó¤§§Î¦¡±Æ°£ (formal carve-out)¡A¨ã¦³¸û¤Ö¤§·N¸q¡C¦b¥»®×¡Aªü´µ§Q±¶§Q±d¡A¤£¶È¨Ï¾Ö¦³±M§QªÌ¡A±q¨Æ¸Óªk©Ò´M¨D¹ªÀy¤§ºë½T³Ð·s¬¡°Ê¡A¥B¸Ó±M§QÅvªÌ¡XÁnºÙÀò±o¬ü°ê FDA ®Ö­ã¤§ÂåÀø¥Î³~¤w¸g¼ô±x©ó¥«³õ¡X¤]­±Á{着¤ñWarner-Lambert©Ò¥D±i¥¼¸g®Ö­ã³\¥i¤§ÃĪ«¥Î³~±M§QÅv¡A

 



[1]. Id. at 1358¡V59.